CLINICAL ROLE -
coagulation counseling
Read More
FOLIC ACID REDUCES RISK OF STROKE
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
FDA APPROVES UPDATED WARFARIN INFO
FONDAPARINUX MAY BE OPTION FOR HIT
INTERACTION REGISTRY AVAILABLE
META-ANALYSIS REINFORCES VALUE OF WARFARIN AND ANTIPLATELET AGENTS
WORLD HEALTH ORGANIZATION STUDIES TRAVEL RISKS
NEW ORAL ANTICOAGULANTS SHOW PROMISE IN PHASE 3 STUDIES
VTE RISK REDUCED WITH LONGER DURATION OF PROPHYLAXIS
WARFARIN-RELATED COMPLICATIONS INCREASE WITH AGE
IS NATTOKINASE A NATURAL ALTERNATIVE TO WARFARIN?
HIGH RATES OF WARFARIN-RELATED AEs IN NURSING HOMES
LONG-TERM ASPIRIN USE MAY REDUCE RISK OF SOME CANCERS
ACETAMINOPHEN INTERACTION MAY PUT PATIENTS AT RISK
FDA APPROVES FIRST BIOLOGIC TO TREAT PROTEIN C DEFICIENCY
LOW-DOSE ASPIRIN BEST FOR PREVENTING CARDIOVASCULAR DISEASE
OUT-OF-RANGE INRs COMMON AMONG WARFARIN PATIENTS IN ER
THE DEBATE CONTINUES ON LENGTH OF THERAPY
METABOLIC SYNDROME MAY CONTRIBUTE TO RISK OF VTE
WOMEN MAY NOT BENEFIT FROM ASPIRIN THERAPY
RACE MAY AFFECT FILLING OF WARFARIN PRESCRIPTIONS
ORAL CORTICOSTEROID THERAPY MAY INCREASE INR
SMOKING AFFECTS WARFARIN THERAPY
NEW ORAL ANTICOAGULANTS UNDER STUDY
ABCD SCORING VALIDATED
ANTICOAGULANT USE SUBOPTIMAL
GENETICS 101: COMMON INHERITED CLOTTING DISORDERS
BEVERAGES MAY BE SOURCE OF INR INSTABILITY
ADVISORY ISSUED REGARDING ANTIPLATELET THERAPY AFTER STENT PLACEMENT